The leading life sciences clusters in Europe September 2015 With the support of © Science|Business 2015

The RESEARCH : A MAPPING project An editorial special report Cluster definition Innovation criteria: Quantitative indicators (Data gathered from Eurostat, the World Bank, OECD, national and regional sources) Qualitative research criteria (e.g. academic excellence, ease to do business) Stakeholder interviews © Science|Business 2015 9/21/2018

Map of the clusters © Science|Business 2015 9/21/2018

INNOVATION success factors Long history of medical research Highly educated workforce State of the art research infrastructures Well-established technology transfer organisations Good interchange/networking between companies, research centres, academic institutes and government agencies © Science|Business 2015 9/21/2018

INNOVATION-driven measures Sustained (financial) government support Tax credit/exemptions for companies engaged in in-house R&D Fast approval for clinical trials Diversification of areas of excellence © Science|Business 2015 9/21/2018

Investments for the future Hagastaden: an innovative city in Sweden One of Stockholm’s largest urban development projects Designed to host a new university hospital; the expansion of the Karolinska Institute Science Park and a new cancer therapy clinic Total investment €6.5 billion including €1 billion from Stockholm city Paris-Saclay: from excellence to innovation Designed to host 22 higher education institutions and research institutes €5 billion investment over 10 years of which €1.3 billion is dedicated to research and innovation programmes and €2.5 billion to scientific and academic buildings Investments for the future © Science|Business 2015 9/21/2018

Investments for the future Francis Crick Institute: The biggest centre for translational biomedical research in Europe A consortium of six of the UK's most successful scientific and academic organisations £650 million investment 1,500 staff, including 1,250 scientists Ireland: a mini-Juncker plan? In 2013, SFI invested €200 million in 7 research centres Leveraging €100 million from industry © Science|Business 2015 9/21/2018

Challenges are country-specific Basic research is underfinanced (Vienna) Lack of tax incentives for companies investing in R&D (Switzerland) Some leading pharma companies are downsizing, and invest less in R&D (e.g. Medicon Valley) Governance and organisational simplification is needed (Paris) Lack of venture capital and difficulties in attracting new sources of capital (Berlin, Munich) Technology transfer is too fragmented across competing institutions and departments (Heidelberg) Shortage of top researchers (Ireland) Lack of skilled management professionals in the life sciences industry (Oslo) Low level of patenting (Stockholm-Uppsala) © Science|Business 2015 9/21/2018

Study available Science|Business website at: http://sciencebusiness.net/OurReports/ Contact: Maryline fiaschi Email: Maryline.fiaschi@sciencebusiness.net TEL: +32 2 880 3045 © Science|Business 2015